GlassScriptPhysician profile
Abdul Qadir
NPI 1891705182
$19,262.63
in general payments reported to CMS, 2019-2025
54 companies · $2,941 in 2025
The $2,941 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $4,454 · 2021: $2,910 · 2022: $2,402 · 2023: $2,321 · 2024: $3,266 · 2025: $2,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,527.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,399.64 | 2019-2025 | |
| Allergan, INC. | $2,848.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $2,484.54 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Lilly USA, LLC | $1,547.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Nestle Healthcare Nutrition INC. | $1,110.27 | 2020-2023 | |
| Pfizer INC. | $967.92 | 2019-2025 | |
| Novo Nordisk INC | $961.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $617.78 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $527.00 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $446.30 | 2023-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $426.48 | 2021-2025 | |
| Amarin Pharma, INC. | $402.93 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $364.59 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $236.48 | 2022-2025 | Zoryve, Seglentis |
| Novartis Pharmaceuticals Corporation | $220.52 | 2019-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.